Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Completed Phase 1 Interventional

Bioavailability of LY03004 and Risperdal® Consta®

NCT02091388
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
LY03004, Risperdal® Consta®
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Little Rock, Arkansas • Long Beach, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Phase 4 Interventional

Improving Work Outcome in People With Recent-onset Schizophrenia

NCT00203788
View directory record Official record
Conditions
Schizophrenia
Interventions
Individual Placement and Support, Workplace Fundamentals Module, Brokered Vocational Rehabilitation, Oral risperidone, Skills training group
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Phase 2 Interventional

Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020

NCT00722176
View directory record Official record
Conditions
Schizophrenia
Interventions
BL-1020, BL-1020 10-30 mg, risperidone
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Phase 4 Interventional

Treatment for First-Episode Schizophrenia

NCT00000374
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
16 Years to 40 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
2
States / cities
Glen Oaks, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 15, 2026, 1:37 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

NCT07145918
View directory record Official record
Conditions
Schizophrenia
Interventions
Emraclidine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Little Rock, Arkansas • Glendale, California • Los Alamitos, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 15, 2026, 1:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Schizophrenia Sensory Gating Deficit With Quetiapine

NCT00536783
View directory record Official record
Conditions
Schizophrenia
Interventions
Quetiapine
Drug
Lead sponsor
New Mexico VA Healthcare System
Federal
Eligibility
18 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 31, 2007 · Synced Oct 15, 2026, 1:37 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Levetiracetam in Early Psychosis

NCT03129360
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Schizophreniform
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Phase 1 Interventional Results available

Lurasidone Pediatric Pharmacokinetics Study

NCT01620060
View directory record Official record
Conditions
Schizophrenia, Autism
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Murrieta, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Not applicable Interventional Results available

Anti-Inflammatory Treatment of Schizophrenia

NCT01514682
View directory record Official record
Conditions
Schizophrenia
Interventions
Anti-inflammatory Combination Therapy, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole in Patients With Schizophrenia

NCT01810783
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

NCT02202213
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Lu AF11167
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 15, 2026, 1:37 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of ANAVEX3-71 in Adults With Schizophrenia

NCT06245213
View directory record Official record
Conditions
Schizophrenia
Interventions
ANAVEX3-71 oral capsules, Placebo oral capsules
Drug
Lead sponsor
Anavex Life Sciences Corp.
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Smoking Relapse Prevention in Schizophrenia

NCT00320697
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Smokers
Interventions
bupropion + nicotine patch + nicotine gum or lozenges, Placebo pill + placebo patch
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 15, 2026, 1:37 PM EDT
Recruiting Not applicable Interventional

TMS for Inhibition Enhancement in Schizophrenia

NCT06155682
View directory record Official record
Conditions
Schizophrenia
Interventions
repetitive transcranial magnetic stimulation (active), repetitive transcranial magnetic stimulation (sham)
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 15, 2026, 1:37 PM EDT
Recruiting Not applicable Interventional

Effectiveness of Motivation Skills Training (MST)

NCT05805397
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Motivation Skills Training, Healthy Behaviors Control Group
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 15, 2026, 1:37 PM EDT
Terminated Phase 1Phase 2 Interventional

Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia

NCT01712646
View directory record Official record
Conditions
Childhood Onset Psychotic Disorders, Schizophrenia
Interventions
Intranasal Oxytocin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
10 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

NCT04972227
View directory record Official record
Conditions
Schizophrenia
Interventions
CY6463, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Not applicable Interventional

Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode

NCT02823041
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Cognitive Training, Aerobic Exercise, Case management and supportive psychotherapy, Individual Placement and Support
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

NCT03034356
View directory record Official record
Conditions
Schizophrenia
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of ∆-9-THC and Naloxone in Humans

NCT01591629
View directory record Official record
Conditions
Healthy
Interventions
Naloxone, Delta-9-THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 15, 2026, 1:37 PM EDT
Completed Phase 2 Interventional

Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients

NCT00097942
View directory record Official record
Conditions
Schizophrenia
Interventions
memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
National City, California • San Diego, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 15, 2026, 1:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)

NCT00211302
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 15, 2026, 1:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Oculomotor and Spatial Cognition Deficits in Schizophrenia

NCT00931996
View directory record Official record
Conditions
Schizophrenia
Interventions
Antipsychotic
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
15 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 15, 2026, 1:37 PM EDT